$100 Million US Push: BDR Pharmaceuticals Plans Strategic Manufacturing Buyouts

The Managing Director and Chairperson of BDR Pharmaceutical, Dharmesh Shah, stated that they are planning to expand their manufacturing buyouts with the US investment of $100 million. The current revenue of the company is around $200 million, which it is planning to list by 2027.

He said, “We are eyeing asset acquisition for manufacturing in the US. We have evaluated a couple of units, and we should be deciding on the acquisition in the next three to four months.” The planning of acquisition will be funded through internal buildups.

According to Shah, they want to manufacture in the US certain enrolled substances and complex molecules. They also prefer to have an establishment there and to do tech transfer and manufacturing, catering locally to the government. The reason to choose the US is to carter the defense sector or the preference for the local producer.

Because of the current geopolitical situation, there is an uncertain path, yet the operating cost in the US is pretty high, with the effect of possible tariffs on exports of pharmaceutical products from India.

To the US market, India is the major supplier of generic medicines, and it exports worth around $9 billion in value 40 percent.

BDR’s substantial business contribution comes from value-added CDMO operations aimed at beneficial sectors, which come under Oncology, critical care, women’s healthcare and dermatology. The company has tie-ups with top Indian companies like Sun Pharma, Cipla, Dr Reddy, Torrent and Zydus. Solid dosage and injectable in cardiology, diabetology, pain management and dermatology. ANDA is going to be commercialized from these of 45 percent or 80 to 90 and evaluating 200 ANDAs in the US.

The company is filing for a new drug delivery system in oncology for geriatric patients and the company has already started the process for FDA approval, the seven filings for complex oncology molecules are lined up this year.